Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reissued by analysts at Cowen in a research report issued on Tuesday.

Other analysts have also recently issued reports about the stock. BMO Capital Markets restated an “outperform” rating and set a $163.00 target price (down from $172.00) on shares of Incyte in a research report on Monday, September 11th. Oppenheimer restated a “hold” rating and set a $135.00 target price on shares of Incyte in a research report on Sunday, September 10th. Goldman Sachs Group started coverage on shares of Incyte in a research report on Friday, October 6th. They set a “buy” rating and a $160.00 target price on the stock. ValuEngine downgraded shares of Incyte from a “hold” rating to a “sell” rating in a report on Wednesday, November 29th. Finally, Evercore ISI started coverage on shares of Incyte in a report on Wednesday, August 16th. They set an “in-line” rating and a $135.00 price target on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Incyte currently has an average rating of “Buy” and a consensus price target of $145.65.

Shares of Incyte (NASDAQ:INCY) traded up $0.03 during mid-day trading on Tuesday, reaching $93.71. 1,430,700 shares of the company’s stock traded hands, compared to its average volume of 1,918,704. Incyte has a 1-year low of $93.49 and a 1-year high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.06 by $0.11. The business had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The business’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. equities analysts expect that Incyte will post -1.33 earnings per share for the current fiscal year.

In related news, EVP Reid M. Huber sold 696 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $98.01, for a total transaction of $68,214.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul A. Friedman sold 28,507 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $105.24, for a total transaction of $3,000,076.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,334 shares of company stock valued at $11,992,011. Corporate insiders own 17.70% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. grew its position in Incyte by 9.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 27,147 shares of the biopharmaceutical company’s stock valued at $3,418,000 after buying an additional 2,455 shares during the period. Pinebridge Investments L.P. lifted its stake in shares of Incyte by 122.0% in the second quarter. Pinebridge Investments L.P. now owns 74,590 shares of the biopharmaceutical company’s stock worth $9,392,000 after buying an additional 40,992 shares in the last quarter. Calamos Advisors LLC lifted its stake in shares of Incyte by 37.7% in the second quarter. Calamos Advisors LLC now owns 113,132 shares of the biopharmaceutical company’s stock worth $14,244,000 after buying an additional 30,990 shares in the last quarter. Inverness Counsel LLC NY purchased a new position in shares of Incyte in the third quarter worth about $330,000. Finally, Tredje AP fonden lifted its stake in shares of Incyte by 63.4% in the second quarter. Tredje AP fonden now owns 22,446 shares of the biopharmaceutical company’s stock worth $2,826,000 after buying an additional 8,706 shares in the last quarter. 90.86% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/incyte-incy-rating-reiterated-by-cowen.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.